Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Lehdistötiedote

Clinics in the US can now purchase Tinearity G1 through a national trading platform

Duearity

Duearity Americas Inc has entered into a partnership with a national distributor in the USA that has a unique digital trading platform for products in the field of hearing health. The distributor has evaluated Tinearity G1 and is now offering Tinearity G1 to clinics throughout the United States.

The distribution company Oaktree Products has evaluated Tinearity G1 and has decided that the product should be included in the company's trading platform, which means that the product can be sold and distributed to clinics throughout the United States. The advantage for Duearity is, firstly, that the distributor is licensed in all states. Secondly, the distributor has high trust among clinics, which puts a stamp of quality on Duearity as a company and Tinearity G1 as a product. Thirdly, the collaboration means that clinics can easily order Tinearity G1 on Oaktree's trading platform. As a consequence, this means a simplified distribution chain where the product is sent directly to clinics via Oaktree. Oaktree Products only sells products in the field of ear and hearing health and only to professionals and clinics.

Duearity Americas Inc are involved in negotiations with more distributors in the US. The goal is to enter into a second distributor agreement during the first quarter of 2024 with a company that has a well-developed sales organization in the US and that covers important sales channels in the country.

For more information, please contact


Fredrik Westman, CEO
+46 738 - 145 215
fredrik.westman@duearity.com 
www.duearity.com

About Duearity AB (publ)


Duearity is a medtech company that develops and produces solutions aiming to relieve tinnitus symptoms and make everyday life easier for those who suffer from tinnitus. The company will offer the products Tinearity and Tinearity-AI.

Tinearity G1 is CE marked, has 510(k) clearance and is sold in the EU and in the US.

Tinearity transmits white noise using non-invasive Bone Conduction Technology to the inner ear in order to relieve symptoms. Tinearity AI will use artificial intelligence to help people anticipate the symptoms and relieve their discomfort.

The company is listed on Nasdaq First North. The company's headquarters are located in Malmö, Sweden.
Certified Adviser is Svensk Kapitalmarknadsgranskning AB (SKMG), www.skmg.se.
www.duearity.com.

Attachments


Clinics in the US can now purchase Tinearity G1 through a national trading platform

Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.